Jing-Ping Liou Selected Research

Histone Deacetylase 6

1/2021	Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells.
12/2018	The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells.
1/2018	The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.
1/2018	5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
1/2018	(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
10/2015	Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
5/2014	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jing-Ping Liou Research Topics

Disease

71	Neoplasms (Cancer) 10/2022 - 06/2002
10	Colorectal Neoplasms (Colorectal Cancer) 12/2021 - 01/2012
10	Leukemia 05/2021 - 07/2010
6	Glioblastoma (Glioblastoma Multiforme) 02/2022 - 10/2017
6	Hypoxia (Hypoxemia) 01/2019 - 07/2013
5	Pancreatic Neoplasms (Pancreatic Cancer) 10/2021 - 01/2016
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2021 - 01/2014
5	Multiple Myeloma 01/2020 - 11/2017
4	Glioma (Gliomas) 10/2022 - 11/2016
4	Inflammation (Inflammations) 01/2022 - 07/2013
4	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020 - 05/2016
4	Neoplasm Metastasis (Metastasis) 01/2019 - 12/2007
3	Prostatic Neoplasms (Prostate Cancer) 12/2021 - 01/2015
3	Stomach Neoplasms (Stomach Cancer) 06/2021 - 10/2007
3	Heart Failure 09/2014 - 10/2013
2	Body Weight (Weight, Body) 01/2022 - 10/2013
2	Lung Neoplasms (Lung Cancer) 12/2021 - 07/2021
2	Hematologic Neoplasms (Hematological Malignancy) 06/2021 - 01/2017
2	Breast Neoplasms (Breast Cancer) 06/2020 - 01/2019
2	Liver Neoplasms (Liver Cancer) 06/2020 - 03/2014
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020 - 03/2015
2	Lymphoma (Lymphomas) 01/2020 - 01/2013
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2018 - 05/2016
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2018 - 07/2015
2	Squamous Cell Carcinoma of Head and Neck 03/2018 - 01/2016
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2018 - 05/2016
2	Alzheimer Disease (Alzheimer's Disease) 01/2018 - 01/2018
2	Colonic Neoplasms (Colon Cancer) 01/2017 - 01/2017
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2017 - 01/2016
2	Hepatocellular Carcinoma (Hepatoma) 01/2016 - 03/2014
2	Carcinoma (Carcinomatosis) 01/2016 - 07/2004
1	Sarcoma (Soft Tissue Sarcoma) 02/2022

Drug/Important Bio-Agent (IBA)

20	Histone Deacetylase InhibitorsIBA 01/2022 - 01/2012
20	Pharmaceutical PreparationsIBA 10/2021 - 01/2003
15	Histone Deacetylases (Histone Deacetylase)IBA 10/2022 - 01/2012
11	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2007
7	Histone Deacetylase 6IBA 01/2021 - 05/2014
5	3- (1- benzenesulfonyl- 2,3- dihydro- 1H- indol- 5- yl)- N- hydroxyacrylamideIBA 01/2022 - 01/2012
5	Antineoplastic Agents (Antineoplastics)IBA 10/2021 - 07/2004
5	Histones (Histone)IBA 02/2020 - 07/2014
5	TubulinIBA 01/2019 - 01/2013
4	Hydroxamic Acids (Hydroxamic Acid)IBA 10/2022 - 02/2017
4	MPT0L145IBA 12/2021 - 05/2016
4	ChromatinIBA 06/2021 - 07/2015
4	Tubulin ModulatorsIBA 01/2018 - 01/2013
3	Messenger RNA (mRNA)IBA 02/2022 - 07/2013
3	quinolineIBA 12/2021 - 04/2017
3	Protein Isoforms (Isoforms)IBA 12/2021 - 04/2018
3	MPT0B291IBA 10/2021 - 01/2020
3	EnzymesIBA 06/2021 - 10/2013
3	entinostat (MS 275)IBA 06/2021 - 04/2020
3	CaspasesIBA 05/2021 - 07/2004
3	Temozolomide (Temodar)FDA LinkGeneric 01/2021 - 10/2017
3	Vincristine (Oncovin)FDA LinkGeneric 04/2020 - 07/2015
3	MPT0G211IBA 01/2019 - 01/2018
3	MPT0B098IBA 03/2018 - 07/2013
3	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 07/2010
3	matrigelIBA 07/2015 - 07/2010
3	Angiotensin IIIBA 09/2014 - 10/2013
3	fosbretabulin (combretastatin A4)IBA 10/2007 - 06/2002
2	CytokinesIBA 06/2022 - 01/2012
2	compound 17IBA 06/2022 - 03/2020
2	RNA-Binding Proteins (RNA-Binding Protein)IBA 02/2022 - 07/2013
2	AfatinibIBA 07/2021 - 03/2020
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2021 - 01/2019
2	N- (2- amino- 5- fluorobenzyl)- 4- (N- (pyridine- 3- acrylyl)aminomethyl)benzamideIBA 04/2021 - 06/2020
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2021 - 01/2017
2	benzamideIBA 06/2020 - 01/2019
2	B7-H1 AntigenIBA 03/2020 - 10/2019
2	Therapeutic UsesIBA 01/2020 - 01/2012
2	Ligases (Synthetase)IBA 01/2020 - 11/2017
2	Oxygen (Dioxygen)IBA 01/2020 - 01/2017
2	Bortezomib (Velcade)FDA Link 01/2019 - 01/2018
2	Matrix Metalloproteinases (MMPs)IBA 01/2019 - 01/2012
2	Metalloproteases (Metalloproteinases)IBA 01/2019 - 01/2012
2	Imatinib Mesylate (Gleevec)FDA Link 01/2017 - 01/2016
2	Cyclin B1IBA 01/2017 - 01/2013
2	BenzenesulfonamidesIBA 01/2017 - 08/2015
2	Vorinostat FDA Link 11/2016 - 07/2015
2	Paclitaxel (Taxol)FDA LinkGeneric 05/2016 - 01/2013
2	2- dimethylamino- N- (1- (4- methoxybenzenesulfonyl)- 2,3- dihydro- 1H- indol- 7- yl)acetamideIBA 05/2016 - 01/2013
2	Propidium (Propidium Iodide)IBA 05/2016 - 07/2004
2	Annexin A5IBA 05/2016 - 07/2004
2	Antimitotic AgentsIBA 01/2016 - 07/2004
2	compound 21IBA 08/2015 - 10/2013
2	CarrageenanIBA 10/2014 - 07/2013
2	Transforming Growth Factors (Transforming Growth Factor)IBA 09/2014 - 10/2013
2	6- methoxy- 3- (3',4',5'- trimethoxybenzoyl)- 1H- indoleIBA 07/2010 - 07/2004
2	2,5- bis(4- hydroxy- 3- methoxybenzylidene)cyclopentanoneIBA 07/2004 - 06/2003
1	Monoamine Oxidase (MAO)IBA 10/2022
1	Oncogene Proteins (Oncogene Protein)IBA 06/2022
1	AntibodiesIBA 06/2022
1	Granzymes (Granzyme)IBA 06/2022
1	Transcription Factors (Transcription Factor)IBA 02/2022
1	ExoribonucleasesIBA 02/2022
1	MicroRNAs (MicroRNA)IBA 02/2022
1	Long Noncoding RNAIBA 02/2022

Therapy/Procedure

22	Therapeutics 10/2022 - 01/2014
3	Drug Therapy (Chemotherapy) 12/2018 - 04/2017
2	Oral Administration 04/2017 - 10/2007